Low-grade neuroendocrine tumor of the corpus uteri

Low-grade neuroendocrine tumor of the corpus uteri is an extremely rare neoplasm arising from neuroendocrine cells within the body of the uterus (corpus uteri). This category encompasses well-differentiated neuroendocrine tumors, sometimes referred to as carcinoid tumors, that develop in the endometrium or myometrium. Unlike high-grade neuroendocrine carcinomas of the uterus, which are aggressive and carry a poor prognosis, low-grade neuroendocrine tumors tend to have a more indolent clinical course, though their behavior can still be unpredictable given the rarity of reported cases. Patients may present with abnormal uterine bleeding, pelvic pain, or the tumor may be discovered incidentally during evaluation for other gynecological conditions. In some cases, neuroendocrine tumors can produce hormones or bioactive substances, potentially leading to symptoms related to hormonal excess, though this is uncommon in uterine primaries. Diagnosis typically requires histopathological examination with immunohistochemical staining for neuroendocrine markers such as chromogranin A, synaptophysin, and CD56. Treatment generally involves surgical resection, most commonly hysterectomy, which may be combined with bilateral salpingo-oophorectomy and lymph node assessment depending on the extent of disease. Due to the extreme rarity of this tumor, there are no standardized treatment guidelines, and management decisions are often extrapolated from experience with neuroendocrine tumors at other anatomical sites and from limited case reports. Adjuvant therapy with chemotherapy or somatostatin analogs may be considered in cases with advanced or metastatic disease, though evidence supporting these approaches in uterine low-grade neuroendocrine tumors remains limited.

Common questions about Low-grade neuroendocrine tumor of the corpus uteri